Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR01344
|
|||||
| Drug Name |
Nalbuphine
|
|||||
| Synonyms |
Intapan; Nalbufina; Nalbuphinum; Intapan (TN); Nalbuphine (INN); Nubain (TN); (5alpha,6alpha)-17-(cyclobutylmethyl)-4,5-epoxymorphinan-3,6,14-triol; 17-cyclobutylmethyl-4,5alpha-epoxymorphinan-3,6alpha,14-triol
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Pain [ICD11: MG30-MG7Z] | Approved | [1] | |||
| Therapeutic Class |
Analgesics
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C21H27NO4
|
|||||
| Canonical SMILES |
C1CC(C1)CN2CCC34C5C(CCC3(C2CC6=C4C(=C(C=C6)O)O5)O)O
|
|||||
| InChI |
InChI=1S/C21H27NO4/c23-14-5-4-13-10-16-21(25)7-6-15(24)19-20(21,17(13)18(14)26-19)8-9-22(16)11-12-2-1-3-12/h4-5,12,15-16,19,23-25H,1-3,6-11H2/t15-,16+,19-,20-,21+/m0/s1
|
|||||
| InChIKey |
NETZHAKZCGBWSS-CEDHKZHLSA-N
|
|||||
| CAS Number |
CAS 20594-83-6
|
|||||
| Pharmaceutical Properties | Molecular Weight | 357.4 | Topological Polar Surface Area | 73.2 | ||
| Heavy Atom Count | 26 | Rotatable Bond Count | 2 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
0.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
9460
, 7980064
, 11056425
, 11466146
, 11467266
, 11485811
, 14828107
, 14828108
, 39341002
, 46507383
, 47216707
, 47291070
, 48110387
, 48259160
, 48416304
, 49698355
, 50968490
, 56464121
, 57359427
, 85787879
, 92308840
, 93166218
, 96024934
, 103234668
, 104000882
, 124893623
, 126666056
, 127291528
, 127291529
, 127291530
, 127291531
, 127291532
, 127291533
, 128691869
, 134223042
, 134337690
, 134993850
, 135650680
, 137005112
, 139813937
, 144205561
, 164230822
, 164763215
, 175267073
, 176484045
, 179116802
, 223663773
, 223893850
, 226395880
, 252354412
|
|||||
| ChEBI ID |
ChEBI:7454
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [2] | |
| References | ||||||
| 1 | Nalbuphine was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther. 2002 Dec;303(3):1029-37. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.